| Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8+ T cell responses following COVID-19 AHE Roukens, CR Pothast, M König, W Huisman, T Dalebout, T Tak, ... Nature Immunology 23 (1), 23-32, 2022 | 81 | 2022 |
| Simultaneous deletion of endogenous TCRαβ for TCR gene therapy creates an improved and safe cellular therapeutic LT Morton, RM Reijmers, AK Wouters, C Kweekel, DFG Remst, ... Molecular Therapy 28 (1), 64-74, 2020 | 72 | 2020 |
| SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells CR Pothast, RC Dijkland, M Thaler, RS Hagedoorn, MGD Kester, ... Elife 11, 2022 | 20 | 2022 |
| Human T cells recognize HLA-DP–bound peptides in two orientations S Klobuch, JJ Lim, P van Balen, MGD Kester, W de Klerk, AH de Ru, ... Proceedings of the National Academy of Sciences 119 (49), e2214331119, 2022 | 12 | 2022 |
| Immune determinants of viral clearance in hospitalised COVID-19 patients: reduced circulating naïve CD4+ T cell counts correspond with delayed viral clearance M Zlei, IA Sidorov, SA Joosten, MHM Heemskerk, SK Myeni, CR Pothast, ... Cells 11 (17), 2743, 2022 | 12 | 2022 |
| Convalescent plasma in a patient with protracted COVID-19 and secondary hypogammaglobulinemia due to chronic lymphocytic leukemia: buying time to develop immunity? JLJ Hanssen, J Stienstra, SA Boers, CR Pothast, HL Zaaijer, JM Tjon, ... Infectious disease reports 13 (4), 855-864, 2021 | 8 | 2021 |
| Increased CD8 T‐cell immunity after COVID‐19 vaccination in lymphoid malignancy patients lacking adequate humoral response: An immune compensation mechanism? LS Boerenkamp, CR Pothast, RC Dijkland, K van Dijk, GNY van Gorkom, ... American Journal of Hematology, 2022 | 4 | 2022 |
| Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial MLM Prins, GVT Roozen, CR Pothast, W Huisman, R van Binnendijk, ... npj Vaccines 9 (1), 1, 2024 | 2 | 2024 |
| Absence of rapid T cell control corresponds with delayed viral clearance in hospitalised COVID-19 patients M Zlei, IA Sidorov, S Joosten, M Heemskerk, SK Myeni, CR Pothast, ... | 1 | 2021 |
| Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose GVT Roozen, MLM Prins, C Prins, JJ Janse, HLM de Gruyter, CR Pothast, ... Clinical Microbiology and Infection, 2024 | | 2024 |
| Binnendi k, R. an, Hartog, G. den,… Roukens MLM Prins, GVT Roozen, CR Pothast, W Huisman HE, 2024 | | 2024 |
| P1536: SARS-COV-2 INFECTIONS IN PATIENTS WITH HAEMATOLOGIC MALIGNANCIES: EFFECT OF VACCINATION AND THE DEVELOPMENT OF HYBRID IMMUNITY S Haggenburg, T Reuvekamp, Q Hofsink, CR Pothast, RC Dijkland, ... HemaSphere 7 (S3), e2387009, 2023 | | 2023 |
| SARS‐CoV‐2 mRNA vaccination of aplastic anemia patients is safe and effective CR Pothast, K van Dijk, ES Pool, CJM Halkes, MHM Heemskerk, ... American Journal of Hematology 98 (2), E20, 2023 | | 2023 |
| Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies CR Pothast, Q Hofsink, S Haggenburg, BS Michel, NJE Haverkate, ... Blood 140 (Supplement 1), 8347-8349, 2022 | | 2022 |
| Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination CR Pothast, Q Hofsink, S Haggenburg, M Bhoekhan, NJE Haverkate, ... Blood 140 (Supplement 1), 1957-1959, 2022 | | 2022 |
| P1570: SARS-COV-2 HUMORAL AND CELLULAR VACCINATION RESPONSE IN PATIENTS WITH LYMPHOID HAEMATOLOGICAL MALIGNANCIES LS Boerenkamp, CR Pothast, RC Dijkland, IH van Loo, L Wieten, ... HemaSphere 6, 1451-1452, 2022 | | 2022 |
| Di k, K. an, Pool, ES, Halkes, C CR Pothast M., Heemskerk, MHM, & T on,. M. L, 2022 | | 2022 |
| SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells (preprint) CR Pothast, RC Dijkland, M Thaler, RS Hagedoorn, MGD Kester, ... | | 2022 |
